These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38353476)

  • 1. Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer.
    Desai A; Smith CJ; Pritchett JC; Leventakos K; West HJ
    Cancer; 2024 Aug; 130(16):2807-2811. PubMed ID: 38353476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.
    Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H
    JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Tanaka H; Makiguchi T; Tozuka T; Kawashima Y; Oba T; Tsugitomi R; Koyama J; Tambo Y; Ogusu S; Saiki M; Gyotoku H; Hasegawa T; Miyauchi E; Sonoda T; Saito R; Nakatomi K; Sakatani T; Kudo K; Tsuchiya-Kawano Y; Nishio M
    Eur J Cancer; 2024 Dec; 213():115117. PubMed ID: 39522333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
    Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.
    Liguori L; Giorgio G; Polcaro G; Pagliara V; Malandrino D; Perri F; Cascella M; Ottaiano A; Conti V; Servetto A; Bianco R; Pepe S; Sabbatino F
    Front Immunol; 2024; 15():1419544. PubMed ID: 39664396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D
    Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China.
    Li H; Yuan Y; Xu Q; Liang G; Hu Z; Li X; Zhang W; Lei H
    Front Immunol; 2024; 15():1487078. PubMed ID: 39635526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.
    Leporati R; Auclin É; Morchón D; Ferriol-Galmés M; Laguna JC; Gorria T; Teixidó C; Aranzazu Amores M; Ambrosini P; Isla D; Russo GL; Mezquita L
    Ther Adv Med Oncol; 2024; 16():17588359241306940. PubMed ID: 39697619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.
    Patel AJ; Hemead H; Law J; Wali A; De Sousa P; Lim E
    Eur J Cancer; 2025 Jan; 214():115118. PubMed ID: 39551030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases.
    Todd CL; Johnson EE; Stewart F; Wallace SA; Bryant A; Woodward S; Norton C
    Cochrane Database Syst Rev; 2024 Oct; 10(10):CD002115. PubMed ID: 39470206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP.
    Su H; Yu C; Sun G; Wang B; Gao Y; Liu X; Song Q; Ma X
    Biomol Biomed; 2024 Dec; 25(1):29-41. PubMed ID: 39036926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.